ZA200306159B - N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists. - Google Patents

N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists. Download PDF

Info

Publication number: ZA200306159B
Authority: ZA; South Africa
Prior art keywords: 4alkyl; 2alkyl; compound according; bromo; fluoro
Prior art date: 2001-02-23

Application number

ZA200306159A

Other languages

English (en)

Inventor

Christopher F Claiborne

David A Claremon

Nigel J Liverton

Kevin T Nguyen

Wayne Thompson

John W Butcher

Brian E Libby

Peter M Munson

Brian Phillips

John A Mccauley

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-23

Filing date

2003-08-08

Publication date

2004-07-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23034191&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200306159(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-08-08 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

2004-07-05 Publication of ZA200306159B publication Critical patent/ZA200306159B/en

Links

HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title description 13
239000005557 antagonist Substances 0.000 title description 13
108010038912 Retinoid X Receptors Proteins 0.000 title description 9
102000034527 Retinoid X Receptors Human genes 0.000 title 1
-1 pyrrolopyrimidinyl Chemical group 0.000 claims description 223
125000001424 substituent group Chemical group 0.000 claims description 153
150000001875 compounds Chemical class 0.000 claims description 82
125000001153 fluoro group Chemical group F* 0.000 claims description 81
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 79
125000003118 aryl group Chemical group 0.000 claims description 67
150000003839 salts Chemical class 0.000 claims description 62
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 47
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 41
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 37
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 36
125000001246 bromo group Chemical group Br* 0.000 claims description 33
125000001309 chloro group Chemical group Cl* 0.000 claims description 33
125000001072 heteroaryl group Chemical group 0.000 claims description 32
208000002193 Pain Diseases 0.000 claims description 13
125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims description 10
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 10
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 9
125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims description 9
125000004429 atom Chemical group 0.000 claims description 8
125000000842 isoxazolyl group Chemical group 0.000 claims description 8
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 8
125000001113 thiadiazolyl group Chemical group 0.000 claims description 8
125000000335 thiazolyl group Chemical group 0.000 claims description 8
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 6
229910007161 Si(CH3)3 Inorganic materials 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
QUIJMHDIAFOPRK-UHFFFAOYSA-N 1-cyclooctylazocane Chemical group C1CCCCCCC1N1CCCCCCC1 QUIJMHDIAFOPRK-UHFFFAOYSA-N 0.000 claims description 3
125000004093 cyano group Chemical group *C#N 0.000 claims description 3
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 22
208000019901 Anxiety disease Diseases 0.000 claims 3
208000019695 Migraine disease Diseases 0.000 claims 3
230000036506 anxiety Effects 0.000 claims 3
206010027599 migraine Diseases 0.000 claims 3
201000000980 schizophrenia Diseases 0.000 claims 3
208000018737 Parkinson disease Diseases 0.000 claims 2
208000006011 Stroke Diseases 0.000 claims 2
239000003814 drug Substances 0.000 claims 2
238000004519 manufacturing process Methods 0.000 claims 2
102100040141 Aminopeptidase O Human genes 0.000 claims 1
108050008333 Aminopeptidase O Proteins 0.000 claims 1
101000608750 Arachis hypogaea Alpha-methyl-mannoside-specific lectin Proteins 0.000 claims 1
241000234435 Lilium Species 0.000 claims 1
241001602876 Nata Species 0.000 claims 1
101000771730 Tropidolaemus wagleri Waglerin-3 Proteins 0.000 claims 1
201000010099 disease Diseases 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
125000003373 pyrazinyl group Chemical group 0.000 claims 1
125000004076 pyridyl group Chemical group 0.000 claims 1
125000000714 pyrimidinyl group Chemical group 0.000 claims 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 26
102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 8
230000000694 effects Effects 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
108020002076 NR2 subfamily Proteins 0.000 description 4
102000038100 NR2 subfamily Human genes 0.000 description 4
125000000753 cycloalkyl group Chemical group 0.000 description 4
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 3
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 3
102000034570 NR1 subfamily Human genes 0.000 description 3
108020001305 NR1 subfamily Proteins 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
208000004547 Hallucinations Diseases 0.000 description 2
108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
229930195712 glutamate Natural products 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
238000000034 method Methods 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
150000002989 phenols Chemical class 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
NZVZVGPYTICZBZ-UHFFFAOYSA-N 1-benzylpiperidine Chemical group C=1C=CC=CC=1CN1CCCCC1 NZVZVGPYTICZBZ-UHFFFAOYSA-N 0.000 description 1
UOUIKYFLNQXAFR-UHFFFAOYSA-N 1h-benzimidazole;piperidine Chemical class C1CCNCC1.C1=CC=C2NC=NC2=C1 UOUIKYFLNQXAFR-UHFFFAOYSA-N 0.000 description 1
CUVGUPIVTLGRGI-UHFFFAOYSA-N 4-(3-phosphonopropyl)piperazine-2-carboxylic acid Chemical compound OC(=O)C1CN(CCCP(O)(O)=O)CCN1 CUVGUPIVTLGRGI-UHFFFAOYSA-N 0.000 description 1
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
206010003591 Ataxia Diseases 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
206010013954 Dysphoria Diseases 0.000 description 1
102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 description 1
102100022631 Glutamate receptor ionotropic, NMDA 2C Human genes 0.000 description 1
102100022626 Glutamate receptor ionotropic, NMDA 2D Human genes 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
108090000862 Ion Channels Proteins 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
108091008644 NR2D Proteins 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
208000004983 Phantom Limb Diseases 0.000 description 1
206010056238 Phantom pain Diseases 0.000 description 1
206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
208000025609 Urogenital disease Diseases 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
229940053202 antiepileptics carboxamide derivative Drugs 0.000 description 1
230000000712 assembly Effects 0.000 description 1
238000000429 assembly Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
150000001556 benzimidazoles Chemical class 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical class OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
108091008634 hepatocyte nuclear factors 4 Proteins 0.000 description 1
150000002460 imidazoles Chemical group 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
239000003446 ligand Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
239000000106 platelet aggregation inhibitor Substances 0.000 description 1
230000002385 psychotomimetic effect Effects 0.000 description 1
UYLWKSJTHLRFBX-UHFFFAOYSA-N purin-6-one Chemical class O=C1N=CN=C2N=CN=C12 UYLWKSJTHLRFBX-UHFFFAOYSA-N 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000036280 sedation Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
208000020431 spinal cord injury Diseases 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
108091008646 testicular receptors Proteins 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2

ZA200306159A 2001-02-23 2003-08-08 N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists. ZA200306159B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US27110001P	2001-02-23	2001-02-23

Publications (1)

Publication Number	Publication Date
ZA200306159B true ZA200306159B (en)	2004-07-05

Family

ID=23034191

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200306159A ZA200306159B (en)	2001-02-23	2003-08-08	N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists.

Country Status (33)

Country	Link
US (2)	US7217716B2 (de)
EP (1)	EP1379520B2 (de)
JP (1)	JP4179879B2 (de)
KR (1)	KR100849839B1 (de)
CN (1)	CN100567293C (de)
AT (1)	ATE324371T1 (de)
AU (1)	AU2002252053B2 (de)
BG (1)	BG108113A (de)
BR (1)	BR0207526A (de)
CA (1)	CA2438895A1 (de)
CZ (1)	CZ20032258A3 (de)
DE (1)	DE60210944T3 (de)
DK (1)	DK1379520T3 (de)
EA (1)	EA005974B1 (de)
EC (1)	ECSP034744A (de)
EE (1)	EE200300403A (de)
ES (1)	ES2261658T3 (de)
GE (1)	GEP20063741B (de)
HR (1)	HRP20030669A2 (de)
HU (1)	HUP0303258A3 (de)
IL (2)	IL157254A0 (de)
IS (1)	IS6902A (de)
MX (1)	MXPA03007621A (de)
NO (1)	NO20033732L (de)
NZ (1)	NZ527365A (de)
PL (1)	PL364625A1 (de)
PT (1)	PT1379520E (de)
SI (1)	SI1379520T1 (de)
SK (1)	SK10542003A3 (de)
UA (1)	UA75392C2 (de)
WO (1)	WO2002068409A1 (de)
YU (1)	YU64303A (de)
ZA (1)	ZA200306159B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002100352A2 (en) *	2001-06-12	2002-12-19	Merck & Co., Inc.	Nr2b receptor antagonists for the treatment or prevention of migraines
WO2003048140A1 (fr) *	2001-12-03	2003-06-12	Japan Tobacco Inc.	Compose azole et utilisation medicinale de celui-ci
TWI329105B (en) *	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
JP2005520821A (ja) *	2002-03-15	2005-07-14	チバ　スペシャルティ　ケミカルズ　ホールディング　インコーポレーテッド	４−アミノピリミジン及び表面の抗菌処理のためのその使用
US6924285B2 (en)	2002-03-30	2005-08-02	Boehringer Ingelheim Pharma Gmbh & Co.	Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
AU2003231359B2 (en)	2002-04-16	2009-04-30	Teijin Limited	Piperidine derivatives having CCR3 antagonism
CN100360521C (zh)	2002-04-25	2008-01-09	帝人株式会社	具有ccr3拮抗作用的4,4-二取代的哌啶衍生物
JP2004315511A (ja) *	2003-03-31	2004-11-11	Taisho Pharmaceut Co Ltd	Ｍｃｈ受容体アンタゴニスト
US7592360B2 (en)	2003-06-04	2009-09-22	Merck & Co., Inc.	3-fluoro-piperidines as NMDA/NR2B antagonists
WO2004108705A1 (en) *	2003-06-04	2004-12-16	Merck & Co., Inc.	3-fluoro-piperidines as nmda/nr2b antagonists
CN1849318B (zh)	2003-07-30	2011-10-12	里格尔药品股份有限公司	用2,4-嘧啶二胺化合物预防和治疗自体免疫疾病的方法
WO2005075439A1 (en)	2004-02-03	2005-08-18	Astrazeneca Ab	Quinazoline derivatives
CN1993363A (zh) *	2004-08-03	2007-07-04	默克公司	1,3－二取代的杂芳基nmda/nr2b拮抗剂
AU2005281783A1 (en) *	2004-09-10	2006-03-16	Ucb Pharma, S.A.	Sigma receptor ligands
US7776869B2 (en)	2004-10-18	2010-08-17	Amgen Inc.	Heteroaryl-substituted alkyne compounds and method of use
NZ564759A (en)	2005-06-30	2011-08-26	Prosidion Ltd	GPCR agonists
JO2769B1 (en)	2005-10-26	2014-03-15	جانسين فارماسوتيكا ان. في	Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
CA2626764A1 (en) *	2005-12-21	2007-06-28	Janssen Pharmaceutica N.V.	Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists
US7935706B2 (en)	2006-02-23	2011-05-03	Shionogi & Co., Ltd.	Nitrogen-containing heterocycle derivatives substituted with cyclic group
JP2009531443A (ja) *	2006-03-29	2009-09-03	フォールドアールエックスファーマシューティカルズインコーポレーティッド	α−シヌクレイン毒性の抑制
EP1921070A1 (de)	2006-11-10	2008-05-14	Boehringer Ingelheim Pharma GmbH & Co. KG	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
JO2642B1 (en)	2006-12-08	2012-06-17	جانسين فارماسوتيكا ان. في	Dopamine 2 receptor antagonists are rapidly hydrolyzed
CA2670375A1 (en) *	2006-12-08	2008-06-12	F. Hoffmann-La Roche Ag	Substituted pyrimidines and their use as jnk modulators
JP5377332B2 (ja)	2007-02-06	2013-12-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
JO2849B1 (en)	2007-02-13	2015-03-15	جانسين فارماسوتيكا ان. في	Dopamine 2 receptor antagonists are rapidly hydrolyzed
MX2009011416A (es) *	2007-04-23	2009-11-05	Janssen Pharmaceutica Nv	Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.
PT2148873E (pt) *	2007-04-23	2012-11-20	Janssen Pharmaceutica Nv	Derivados da 4-alcoxipiridazina antagonistas de dissociação rápida do recetor da dopamina 2
PL2195293T3 (pl)	2007-08-22	2014-03-31	Astrazeneca Ab	Pochodne cyklopropyloamidu
EP2215073A4 (de) *	2007-10-31	2011-04-06	Merck Sharp & Dohme	Schlafmodulation mit nr2b-rezeptorantagonisten
MX2010008621A (es)	2008-02-07	2010-09-24	Boehringer Ingelheim Int	Heterociclos espirociclicos, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparacion.
CA2723989C (en)	2008-05-13	2017-04-25	Astrazeneca Ab	Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
WO2010000456A1 (en)	2008-07-03	2010-01-07	Janssen Pharmaceutica Nv	Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists
CN102171189B (zh)	2008-07-31	2013-11-20	詹森药业有限公司	作为快速解离多巴胺2受体拮抗剂的哌嗪-1-基-三氟甲基取代的吡啶
CA2733153C (en)	2008-08-08	2016-11-08	Boehringer Ingelheim International Gmbh	Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
TW201039825A (en)	2009-02-20	2010-11-16	Astrazeneca Ab	Cyclopropyl amide derivatives 983
US8389536B2 (en) *	2009-10-27	2013-03-05	Hoffmann-La Roche Inc.	Positive allosteric modulators (PAM)
RU2012136921A (ru) *	2010-02-18	2014-03-27	Астразенека Аб	Твердые формы, содержащие производные циклопропиламида
WO2011102794A1 (en)	2010-02-18	2011-08-25	Astrazeneca Ab	Processes for making cyclopropyl amide derivatives and intermediates associated therewith
AU2010363329A1 (en)	2010-11-07	2013-05-09	Targegen, Inc.	Compositions and methods for treating myelofibrosis
ES2571741T3 (es) *	2011-03-31	2016-05-26	Bayer Ip Gmbh	Bencimidazoles sustituidos como inhibidores de Mps-1 quinasa
US8722670B2 (en) *	2011-09-30	2014-05-13	Bristol-Myers Squibb Company	Selective NR2B antagonists
ES2627541T3 (es)	2012-04-20	2017-07-28	Ucb Pharma, S.A.	Métodos para tratar la enfermedad de Parkinson
JP2016028017A (ja) *	2012-12-13	2016-02-25	大正製薬株式会社	フッ素置換ピペリジン化合物
JP2017001954A (ja) *	2013-11-08	2017-01-05	石原産業株式会社	含窒素飽和複素環化合物
EP3150598B1 (de) *	2014-05-28	2019-02-13	TOA Eiyo Ltd.	Substituierte tropanderivate
WO2015187845A1 (en) *	2014-06-04	2015-12-10	Rugen Holdings (Cayman) Limited	Difluoroethylpyridine derivatives as nr2b nmda receptor antagonists
CA2957898C (en) *	2014-09-15	2023-02-21	Rugen Holdings (Cayman) Limited	Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists
WO2016100349A2 (en) *	2014-12-16	2016-06-23	Rugen Holdings (Cayman) Limited	Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
EP3253761A4 (de)	2015-02-04	2018-06-20	Rugen Holdings (Cayman) Limited	3,3-difluor-piperidinderivate als nr2b-nmda-rezeptorantagonisten
US10584102B2 (en)	2015-05-11	2020-03-10	Basf Se	Process for preparing 4-amino-pyridazines
AR104837A1 (es) *	2015-06-01	2017-08-16	Rugen Holdings (Cayman) Ltd	Compuestos heterocíclicos de 3,3-difluorpiperidina carbamato como antagonistas del receptor de nmda nr2b
US11000526B2 (en)	2016-11-22	2021-05-11	Rugen Holdings (Cayman) Limited	Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
BR112020017159A2 (pt)	2018-02-23	2020-12-22	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Inibidores de glutaminil ciclases bacterianas para uso no tratamento de doenças periodontais e relacionadas

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL265777A (de) *	1960-06-09
DE2341965C3 (de)	1973-08-20	1979-01-25	C.H. Boehringer Sohn, 6507 Ingelheim	4- [N- (o-PyridyD- N-acyl] -aminolphenäthylpiperidine, Verfahren zu deren Herstellung sowie deren Verwendung bei der Bekämpfung von Schmerzzuständen
US4197304A (en) *	1975-09-23	1980-04-08	Janssen Pharmaceutica N.V.	N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides
EP0126087A1 (de) *	1982-09-24	1984-11-28	Beecham Group Plc	Amino-azabicycloalkyl-derivate als dopamin-antagonisten
WO1991012005A1 (en)	1990-02-06	1991-08-22	Pfizer Inc.	Neuroprotective 3-piperidino-4-hydroxychroman derivatives and analogs
US5306723A (en)	1990-05-10	1994-04-26	Pfizer Inc.	Neuroprotective indolone and related derivatives
US5189036A (en)	1990-06-20	1993-02-23	Schering Ag	Imidazolylbenzoyl substituted heterocycles
DE9290042U1 (de)	1991-04-18	1993-12-16	Pfizer	Pro-Arzneimittelester von phenolischen 2-Piperidino-1-alkanolen
CA2113568A1 (en)	1991-07-17	1993-02-04	Willard Mckowan Welch Jr.	2-(4-hydroxypiperidino)-1-alkanol derivatives as antiischemic agents
MY110227A (en)	1991-08-12	1998-03-31	Ciba Geigy Ag	1-acylpiperindine compounds.
SI9300097B (en) *	1992-02-27	2001-12-31	Janssen Pharmaceutica Nv	(benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
DK55192D0 (da) *	1992-04-28	1992-04-28	Lundbeck & Co As H	1-piperazino-1,2-dihydroindenderivater
US5436255A (en)	1992-07-23	1995-07-25	Pfizer Inc.	Method of treating diseases susceptable to treatment by blocking NMDA-receptors
DE4241632A1 (de)	1992-12-10	1994-06-16	Thomae Gmbh Dr K	Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
NZ259802A (en)	1992-12-21	1997-10-24	Smithkline Beecham Corp	Bicyclic derivatives and pharmaceutical compositions
DE4304650A1 (de)	1993-02-16	1994-08-18	Thomae Gmbh Dr K	Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0687249A1 (de)	1993-03-03	1995-12-20	Eli Lilly And Company	Balanoide als proteinkinase c inhibitoren
ATE171447T1 (de)	1993-03-18	1998-10-15	Merck Sharp & Dohme	Benzimidazole derivate
AU3138595A (en)	1994-07-20	1996-02-16	Acea Pharmaceuticals, Inc.	Haloperidol analogs and the use thereof
US5661161A (en)	1994-09-29	1997-08-26	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
EP0742208A1 (de)	1995-05-05	1996-11-13	Grelan Pharmaceutical Co., Ltd.	2-Ureido-benzamid-Derivate
PT828513E (pt)	1995-05-26	2004-05-31	Pfizer	Combinacoes contendo antagonistas selectivos de nmda para o tratamento do parkinsonismo
DE19541264A1 (de)	1995-11-06	1997-05-07	Bayer Ag	Purin-6-on-derivate
EP0771779B1 (de)	1995-11-06	2002-05-02	Kuraray Co., Ltd.	Verfahren zur Herstellung von Acetalen
GB9523675D0 (en) *	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
ZA9610745B (en)	1995-12-22	1997-06-24	Warner Lambert Co	4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
FR2744449B1 (fr)	1996-02-02	1998-04-24	Pf Medicament	Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
EP0787493A1 (de)	1996-02-03	1997-08-06	F. Hoffmann-La Roche Ag	Tetrahydroisochinolin-Derivate
TW504510B (en) *	1996-05-10	2002-10-01	Janssen Pharmaceutica Nv	2,4-diaminopyrimidine derivatives
WO1997045119A1 (en)	1996-05-24	1997-12-04	Novartis Ag	Use of substance p antagonists for treating social phobia
NZ333904A (en)	1996-07-25	2000-06-23	Biogen Inc	VLA-4 and IIb/IIIa cell adhesion inhibitors
DZ2285A1 (fr)	1996-08-08	2002-12-25	Smithkline Beecham Corp	Inhibiteurs de protéase de la cystéine.
EP0846683B1 (de)	1996-12-03	2001-09-19	F. Hoffmann-La Roche Ag	4-Hydroxypiperidinderivate
FR2758328B1 (fr)	1997-01-15	1999-04-02	Pf Medicament	Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments
FR2758327B1 (fr)	1997-01-15	1999-04-02	Pf Medicament	Nouvelles arylpiperazines derivees de piperidine
IT1291569B1 (it)	1997-04-15	1999-01-11	Angelini Ricerche Spa	Indazolammidi come agenti serotoninergici
AU1415099A (en)	1997-11-18	1999-06-07	Merck & Co., Inc.	4-substituted-4-piperidine carboxamide derivatives
US6020347A (en)	1997-11-18	2000-02-01	Merck & Co., Inc.	4-substituted-4-piperidine carboxamide derivatives
DE19815026A1 (de) *	1998-04-03	1999-10-07	Hoechst Schering Agrevo Gmbh	Substituierte Piperidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
PE20000728A1 (es)	1998-06-26	2000-08-21	Cocensys Inc	Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
ATE279407T1 (de)	1998-08-07	2004-10-15	Applied Research Systems	Fsh mimetika zur behandlung von infertilität
DE19838300A1 (de)	1998-08-24	2000-03-02	Bayer Ag	9-Dialkylaminopurinon-derivate
US6303637B1 (en)	1998-10-30	2001-10-16	Merck & Co., Inc.	Heterocyclic potassium channel inhibitors
US7125883B1 (en)	1999-04-13	2006-10-24	Abbott Gmbh & Co. Kg	Integrin receptor ligands
JP2003503351A (ja)	1999-06-30	2003-01-28	メルクエンドカムパニーインコーポレーテッド	Ｓｒｃキナーゼ阻害化合物

2002
- 2002-02-20 US US10/470,561 patent/US7217716B2/en not_active Expired - Fee Related
- 2002-02-20 PL PL02364625A patent/PL364625A1/xx not_active Application Discontinuation
- 2002-02-20 HU HU0303258A patent/HUP0303258A3/hu unknown
- 2002-02-20 ES ES02721105T patent/ES2261658T3/es not_active Expired - Lifetime
- 2002-02-20 WO PCT/US2002/005226 patent/WO2002068409A1/en active IP Right Grant
- 2002-02-20 EP EP02721105.1A patent/EP1379520B2/de not_active Expired - Lifetime
- 2002-02-20 PT PT02721105T patent/PT1379520E/pt unknown
- 2002-02-20 SK SK1054-2003A patent/SK10542003A3/sk not_active Application Discontinuation
- 2002-02-20 US US10/079,452 patent/US7053089B2/en not_active Expired - Lifetime
- 2002-02-20 EE EEP200300403A patent/EE200300403A/xx unknown
- 2002-02-20 CN CNB028087135A patent/CN100567293C/zh not_active Expired - Fee Related
- 2002-02-20 UA UA2003098659A patent/UA75392C2/uk unknown
- 2002-02-20 AU AU2002252053A patent/AU2002252053B2/en not_active Ceased
- 2002-02-20 CA CA002438895A patent/CA2438895A1/en not_active Abandoned
- 2002-02-20 IL IL15725402A patent/IL157254A0/xx active IP Right Grant
- 2002-02-20 CZ CZ20032258A patent/CZ20032258A3/cs unknown
- 2002-02-20 GE GE5284A patent/GEP20063741B/en unknown
- 2002-02-20 NZ NZ527365A patent/NZ527365A/en unknown
- 2002-02-20 BR BR0207526-1A patent/BR0207526A/pt not_active IP Right Cessation
- 2002-02-20 JP JP2002567923A patent/JP4179879B2/ja not_active Expired - Fee Related
- 2002-02-20 KR KR1020037011079A patent/KR100849839B1/ko not_active IP Right Cessation
- 2002-02-20 SI SI200230322T patent/SI1379520T1/sl unknown
- 2002-02-20 YU YU64303A patent/YU64303A/sh unknown
- 2002-02-20 AT AT02721105T patent/ATE324371T1/de not_active IP Right Cessation
- 2002-02-20 DK DK02721105T patent/DK1379520T3/da active
- 2002-02-20 MX MXPA03007621A patent/MXPA03007621A/es active IP Right Grant
- 2002-02-20 DE DE60210944.2T patent/DE60210944T3/de not_active Expired - Lifetime
- 2002-02-20 EA EA200300919A patent/EA005974B1/ru not_active IP Right Cessation
2003
- 2003-07-31 IS IS6902A patent/IS6902A/is unknown
- 2003-08-05 IL IL157254A patent/IL157254A/en not_active IP Right Cessation
- 2003-08-08 ZA ZA200306159A patent/ZA200306159B/en unknown
- 2003-08-19 BG BG108113A patent/BG108113A/bg unknown
- 2003-08-22 NO NO20033732A patent/NO20033732L/no not_active Application Discontinuation
- 2003-08-22 EC EC2003004744A patent/ECSP034744A/es unknown
- 2003-08-22 HR HR20030669A patent/HRP20030669A2/hr not_active Application Discontinuation

Also Published As

Publication number	Publication date
BR0207526A (pt)	2004-03-09
JP2004524314A (ja)	2004-08-12
BG108113A (bg)	2005-04-30
PT1379520E (pt)	2006-08-31
NO20033732D0 (no)	2003-08-22
DE60210944T2 (de)	2007-04-19
EP1379520B2 (de)	2014-04-09
EA200300919A1 (ru)	2004-02-26
KR20030076703A (ko)	2003-09-26
NO20033732L (no)	2003-10-22
SK10542003A3 (sk)	2004-03-02
YU64303A (sh)	2006-05-25
HRP20030669A2 (en)	2005-06-30
IS6902A (is)	2003-07-31
DE60210944T3 (de)	2015-07-23
CN100567293C (zh)	2009-12-09
UA75392C2 (en)	2006-04-17
WO2002068409A1 (en)	2002-09-06
US20020165241A1 (en)	2002-11-07
PL364625A1 (en)	2004-12-13
IL157254A0 (en)	2004-02-19
GEP20063741B (en)	2006-02-10
IL157254A (en)	2008-11-26
AU2002252053B2 (en)	2006-09-14
ATE324371T1 (de)	2006-05-15
EP1379520A1 (de)	2004-01-14
EP1379520B1 (de)	2006-04-26
DE60210944D1 (de)	2006-06-01
MXPA03007621A (es)	2003-12-04
ES2261658T3 (es)	2006-11-16
EE200300403A (et)	2003-12-15
ECSP034744A (es)	2003-10-28
KR100849839B1 (ko)	2008-08-01
US7217716B2 (en)	2007-05-15
EA005974B1 (ru)	2005-08-25
DK1379520T3 (da)	2006-08-21
JP4179879B2 (ja)	2008-11-12
CN1503793A (zh)	2004-06-09
CZ20032258A3 (cs)	2004-01-14
HUP0303258A2 (hu)	2004-01-28
CA2438895A1 (en)	2002-09-06
US7053089B2 (en)	2006-05-30
NZ527365A (en)	2005-08-26
SI1379520T1 (sl)	2006-08-31
US20040209889A1 (en)	2004-10-21
HUP0303258A3 (en)	2004-06-28
AU2002252053C1 (en)	2002-09-12

Publication	Publication Date	Title
ZA200306159B (en)	2004-07-05	N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists.
KR20240021884A (ko)	2024-02-19	암을 치료하기 위한 parp 억제제와 조합된 atr 억제제의 용도
US20190152974A1 (en)	2019-05-23	Substituted pteridines useful for the treatment and prevention of viral infections
AU771460B2 (en)	2004-03-25	Thrombopoietin mimetics
EP0742715B1 (de)	1999-04-07	Fluessige oral anzuwendende arzneizubereitungen enthaltend paroxetinresinate
ES2257090T3 (es)	2006-07-16	Poliamidas ciclicas para tratar trombocitopenia.
ES2267715T3 (es)	2007-03-16	Derivados aminados de dihidro-1,3,5-triazina utiles en el tratamiento de patologias asociadas al sindrome de resistencia a la insulina.
FI109118B (fi)	2002-05-31	Menetelmä serotoniiniantagonisteina toimivien N-syano-N'-pyridyyliguanidiinien valmistamiseksi
ES2293324T3 (es)	2008-03-16	Derivados de pteridina para el tratamiento de enfermedades relativas al tnf-alpha.
HUP0203965A2 (en)	2003-05-28	Indazole compounds and pharmaceutical compositions containing them
US20130224151A1 (en)	2013-08-29	Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
HUP0202490A2 (hu)	2002-11-28	Indazolszármazékok és ezeket tartalmazó protein-kináz gátló hatású gyógyszerkészítmények
CN103347517A (zh)	2013-10-09	治疗帕金森病中运动障碍的新型d3 多巴胺受体激动剂
JP2023506787A (ja)	2023-02-20	Ｐａｒｐ阻害薬と組み合わせたａｔｒ阻害薬の使用
RU2008127260A (ru)	2010-01-20	Производные хиназолинона в качестве антагонистов ваниллоидов
US9060967B2 (en)	2015-06-23	Stable aqueous formulation of (E)-4-carboxystyryl-4-chlorobenzyl sulfone
RU2011139157A (ru)	2013-04-20	Производное трициклического пиразолопиримидина
WO2017100703A1 (en)	2017-06-15	Ems analogues of lyn/src-tyrosine kinase inhibitors
EP4101468A1 (de)	2022-12-14	Zusammensetzung für antikrebsmittel
US20100130525A1 (en)	2010-05-27	Aqueous solution preparation containing camptothecin compounds
US20210221817A1 (en)	2021-07-22	Novel heteroaromatic compounds as potent modulators of the hippo-yap signaling pathway lats1/2 kinases
JP2011225510A (ja)	2011-11-10	新規な抗腫瘍剤
EP3512520B1 (de)	2023-06-21	Dithio-derivate von epidithiodiketopiperazine (etp)
RU2328306C2 (ru)	2008-07-10	Комбинированная противоопухолевая терапия замещенными производными акрилоилдистамицина и ингибиторами протеинкиназ (серин-/треонинкиназы)
CN102875479B (zh)	2015-06-10	喹唑啉二酮衍生物及其制备方法、其药物组合物及用途